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The HMGA2 protein belongs to the HMGA family of architectural transcription factors, which play an
important role in chromatin organization. HMGA proteins are overexpressed in several experimental and
human tumors and have been implicated in the process of neoplastic transformation. Hmga2 knockout results
in the pygmy phenotype in mice and in a decreased growth rate of embryonic fibroblasts, thus indicating a role
for HMGA2 in cell proliferation. Here we show that HMGA2 associates with the E1A-regulated transcriptional
repressor p120E4F, interfering with p120E4F binding to the cyclin A promoter. Ectopic expression of HMGA2
results in the activation of the cyclin A promoter and induction of the endogenous cyclin A gene. In addition,
chromatin immunoprecipitation experiments show that HMGA2 associates with the cyclin A promoter only
when the gene is transcriptionally activated. These data identify the cyclin A gene as a cellular target for
HMGA2 and, for the first time, suggest a mechanism for HMGA2-dependent cell cycle regulation.
HMGA2 belongs, together with HMGA1a and HMGA1b,
to the HMGA family of nuclear proteins, whose expression has
functional implications in the pathogenesis of several human
tumors (2, 20, 47, 50). A strong association between the ex-
pression of these proteins and the transformed phenotype has
been observed since they were first described, in transformed
rat thyroid cells (24, 25), and was later found in several human
neoplasias (e.g., colon, prostate, cervical, and thyroid carcino-
mas) (4, 10, 17, 51). Their expression is very low, if not absent,
in adult tissues and is restricted to embryogenesis (11, 28, 32,
55).
The first evidence of a direct role played by these factors in
tumorigenesis came from transfection of an antisense con-
struct for HMGA2 in normal rat thyroid cells that prevented
the neoplastic transformation induced by myeloproliferative
sarcoma virus and kirsten murine sarcoma virus (7). More
recently, the increased expression of all three HMGA family
members was shown to lead to transformation with anchorage-
independent cell growth (53, 54), and the overexpression of
HMGA1 was also shown to promote tumor progression in
human breast epithelial cells (41). Of additional interest, re-
arrangements of the HMGA2 gene, resulting in the loss of the
acidic C-terminal tail, have been frequently detected in benign
human tumors of mesenchimal origin (50). Indeed, transgenic
mice expressing the truncated HMGA2 protein develop tu-
mors such as lipomas and natural killer lymphomas (1, 3, 6,
18), while mice expressing wild-type HMGA2 develop pituitary
adenomas (19).
Despite this evidence, the molecular events and the precise
role played by HMGA2 in cell proliferation and tumorigenesis
still need to be defined.
HMGA proteins contain about 100 amino acid residues and
have three DNA-binding domains which have been named AT
hooks because of their ability to interact with the narrow minor
groove of AT-rich DNA sequences (42). These nuclear pro-
teins, by binding to DNA and/or to transcription factors, can
organize the assembly of nucleoprotein-DNA transcriptional
complexes (called enhanceosomes) at the level of enhancers or
promoters, resulting in enhancement or repression of tran-
scription. For this reason, they are referred to as architectural
transcription factors (42).
Since a critical step in the assembly of enhanceosomes is the
ability of HMGA to establish protein-protein interactions with
other nuclear factors, we used different approaches to search
for new HMGA2-interacting proteins and identified the tran-
scription factor p120E4F. p120E4F is a ubiquitously expressed
GLI-Kru¨ppel-related mammalian transcription factor which
was first identified as a cellular factor binding to regulatory
regions of the adenovirus E4 promoter and which is responsi-
ble for E4 regulation of expression in the course of adenoviral
infection (21). p120E4F is likely to play a key role in mamma-
lian cell cycle control. In fact, ectopic expression of p120E4F
leads to growth suppression, an effect which is mediated by the
interaction with the tumor suppressors pRB (15), p14ARF
(43), and p53 (46). Moreover, overexpression of p120E4F in
NIH 3T3 cells inhibits progression from G1 to S phase by a
mechanism that involves the repression of cyclin A (16). This
effect is mediated by p120E4F binding to a cyclic AMP-respon-
sive element (CRE) which is required for full transcriptional
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activation of cyclin A gene (5, 13). The CRE site is also rec-
ognized by CREB and ATF family members, raising the ques-
tion of how the access of these factors to DNA is modulated.
Here we report that HMGA2 associates in vitro and in vivo
with p120E4F. Ectopic expression of HMGA2 activates the
cyclin A promoter, counteracting the repressing activity of
p120E4F exerted through the CRE element. Moreover, we
show that HMGA2 is able to induce the expression of the
endogenous cyclin A gene. Finally, chromatin immunoprecipi-
tation experiments indicate that association of HMGA2 with
the promoter is regulated during the cell cycle, positively cor-
relating with transcriptional activation. The identification of
cyclin A, a key factor in cell cycle control, as a functional
cellular target for HMGA2 provides for the first time a mech-
anism that might reveal the oncogenic functions of this factor.
MATERIALS AND METHODS
Cell lines. All of the cell lines used were grown at 37°C in a humidified 5%
CO2 incubator in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum (FCS), 2 mM L-glutamine, penicillin (100 U/ml), and strepto-
mycin (100 g/ml). CHO is a Chinese hamster ovary cell line, 293 is a human
embryonic kidney cell line, and SaOS-2 is a human osteosarcoma cell line.
Plasmids. Plasmids pGEX HMGA2, pGEX TRX44/63, and pGEX TRX53/72
expressing the human HMGA2 and two HMGA2 peptides within the Escherichia
coli thioredoxin in fusion with the glutathione S-transferase (GST) were already
described (36). Plasmids pcDNA3HA-E4F 2.5K, -E4F 694, -E4F 551, -E4F 427,
-E4F 60-358, -E4F 262, -E4F 162, -E4F 60-783, and -E4F 350-783, express-
ing wild-type p120E4F and deletion mutants in frame with a hemagglutinin (HA)
epitope used for in vitro translation and transfections, were described previously
(46). pcDNA3HA-E4F 153-299 was generated by PCR with pcDNA3HA-E4F
2.5K as a template and the primers 5-CTGCTGAATTCGAGCTGGGAGAC
GGTGAGA-3 and 5-CCAATAGTCTAGATCCAGCTCCAGAACCTG-3.
pGEX E4F 60-358 was obtained by cloning the sequence coding for the dele-
tion mutant 60-358 into the EcoRI restriction site of the pGEX-4T1 vector.
Plasmids pAR HMGA2wt, pAR HMGA294, pAR HMGA283, pAR
HMGA2MAD, pAR HMGA273, pAR HMGA254, and pAR HMGA243, used for
the expression of recombinant proteins used in far-Western experiments, were
described previously (36). The pcDNA3HA-HMGA2 and pcDNA3-HMGA2
plasmids for the expression of wild-type HMGA2 in transfection experiments
were obtained by cloning the HMGA2 open reading frame into the BamHI and
XhoI restriction sites of the pcDNA3HA vector and the BamHI site of the
pcDNA3 vector, respectively.
The CycAwt reporter plasmid was obtained by cloning into the KpnI and
HindIII restriction sites of the pGL2Basic vector a 213-bp fragment of the human
cyclin A promoter (from bp 165 to 48 relative to the most 3 transcription
initiation site), which was generated by PCR with oligonucleotides 5-CTCCG
GTACCAGCCAGTTTGTTTCTC-3 and 5-TGGCAAGCTTAAGACGCCC
AGAGATG-3. The CycAmut reporter plasmid was obtained by using a splice
overlap extension PCR technique with the internal oligonucleotides 5-TTGAC
TCGAGTCAAGGCCGCGAGCGCTTT-3 and 5-CCTTGACTCGAGTCAA
GGCGACAGGGTCA-3, in order to mutate the CRE site with the insertion of
an XhoI restriction site (underlined).
GST pull-down assays and far-Western blot analysis. Expression and purifi-
cation of GST fusion proteins for GST pull-down assays were carried out by
standard protocols. Proteins were translated in vitro by using a commercial in
vitro transcription-translation kit (TNT; Promega), with [35S]methionine (NEN
Life Science) according to the manufacturer’s instructions. GST pull-down assays
were carried out essentially as described previously (36). For far-Western exper-
iments, recombinant HMGA2 proteins were expressed and purified as previously
described (33). One microgram of each of the HMGA2 recombinant proteins
was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to a polyvinylidene difluoride membrane. Far-
Western blotting was then carried out as described previously (36).
Immunoprecipitation and Western blot analysis. Subconfluent 293 cells
seeded on 100-mm-diameter petri dishes were transfected with the indicated
expression vectors by the conventional calcium phosphate procedure. Thirty-six
hours later, cells were washed with ice-cold phosphate-buffered saline and then
harvested in 1 ml of ice-cold lysis buffer (150 mM NaCl, 50 mM Tris HCl [pH
7.5], 0.5% NP-40, 10% glycerol) supplemented with 1 mM phenylmethylsulfonyl
fluoride and protease inhibitors. Lysis was performed at 4°C for 20 min. The
lysates were then clarified by centrifugation and incubated for 3 h at 4°C with
anti-HMGA2 antibody (36) prebound to 20 l of protein A–Sepharose CL-4B
(Amersham Biosciences). The beads were then washed three times in 1 ml of
ice-cold lysis buffer, and the bound proteins were solubilized by addition of 20 l
of SDS-containing sample buffer. Western blot analysis was performed by stan-
dard procedures with anti-HA primary antibody (Roche). Bound primary anti-
bodies were visualized by enhanced chemiluminescence.
Transfections, luciferase assays, and immunocytochemical analysis. Transfec-
tions were performed by the standard calcium phosphate precipitation method.
CHO cells were plated at a density of 0.7  106 cells per 60-mm-diameter culture
dish and processed 32 h after removal of the precipitates. For luciferase assay,
cells were transfected with 1 g of the reporter construct, the indicated amount
of the expression vectors, and 0.1 g of pRL-CMV Renilla luciferase expression
vector (Promega) to normalize for transfection efficiencies. The assay was per-
formed with the dual-luciferase reporter assay system (Promega) according to
the manufacturer’s instructions.
For immunocytochemistry, SaOS-2 cells were plated 24 h before transfection
at a density of 0.5  106 cells per 60-mm-diameter culture dish with a glass
coverslip and transfected with 5 g of pcDNA3HA-HMGA2 expression vector.
At 32 h after removal of the precipitates, cells were fixed with 3% paraformal-
dehyde, permeabilized with 0.3% Triton X-100, and incubated with an anti
HA-specific mouse monoclonal antibody (Roche) and an anti-cyclin A rabbit
polyclonal antibody (Santa Cruz Biotechnology, Inc.). Immunofluorescence was
monitored by incubation with an anti-mouse Cy3-conjugated secondary antibody
(Sigma) and an anti-rabbit fluorescein isothiocyanate-conjugated secondary an-
tibody (Sigma). Nuclei were stained with DAPI (4,6-diamidino-2-phenylin-
dole).
RT-PCR. SaOS-2 cells were plated 24 h before transfection in 100-mm-diam-
eter culture dishes and transfected with 5 g of pcDNA3HA-HMGA2 or
pcDNA3HA expression vector. At 36 h after transfection, RNA was extracted by
the guanidinium thiocyanate method, and reverse transcription (RT) was per-
formed in a final volume of 50 l with 2 g of total RNA, 50 nmol of random
nonamer primers (Sigma), 1 reaction buffer, and 200 U of Moloney murine
leukemia virus reverse transcriptase (RNase H Minus; Promega). Twenty-five
cycles of PCR were performed in a 50-l volume with 10 l of the RT mixture,
0.05 l of [-32P]dCTP (Perkin-Elmer Life Science), 1 PCR buffer, and 50
pmol of each cyclin A primer or 5 pmol of each GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) primer. cDNA templates were incubated for 4 min at
94°C and amplified with cycles of 92°C for 1 min, 45°C for 1 min, and 75°C for
90 s, with a final extension for 5 min at 75°C. In order to compare the PCR
products semiquantitatively, 20 to 30 PCR cycles were performed to determine
the linearity of the PCR amplification, and the amplified GAPDH cDNA served
as an internal control for cDNA quantity and quality. The primers for cyclin A
were 5-GCCATTAGTTTACCTGGACCCAGA-3 and 5-CACTGACATGGA
AGACAGGAACCT-3, and those for GAPDH were 5-CAGCGACACCCAC
TCCTCCACCTT-3 and 5-CATGAGGTCCACCACCCTGTTGCT-3. Ampli-
fied PCR products were separated on an 8% polyacrylamide gel in 0.5 Tris-
borate-EDTA buffer and visualized by autoradiography. Amplification yielded
amplified fragments of the predicted sizes (cyclin A, 354 bp; GAPDH, 124 bp).
EMSAs. The indicated amounts of purified recombinant GST-E4F 60-358
were incubated with 32P-labeled DNA in 20 l of binding buffer containing 20
mM HEPES (pH 7.9), 50 mM KCl, 1 mM MgCl2, 0.1 mM EDTA, 5 mM
dithiothreitol, 0.4 mM ZnCl2, 0.25 mg of bovine serum albumin per ml, and 4%
glycerol. For competition binding reactions, the unlabeled competitors were
included in the reaction mixtures at the indicated molar excess. When assayed,
high-pressure liquid chromatography-purified recombinant HMGA2wt and BSA
proteins were included in the indicated amounts. After incubation for 20 min at
room temperature, samples were loaded onto a native 6% polyacrylamide gel in
0.5 Tris-borate-EDTA buffer, electrophoresed at 4°C at 15 V/cm, dried, and
exposed to X-ray film (Hyperfilm MP; Amersham Biosciences). The following
oligonucleotides (only the upper strand is shown) were used in electrophoretic
mobility shift assay (EMSA) experiments: CycAwt, 5-TGTCGCCTTGAATGA
CGTCAAGGCCGCGA-3; CycAmut, 5-TGTCGCCTTGACTCGAGTCAAG
GCCGCGA-3.
Chromatin immunoprecipitation. Chromatin immunoprecipitations were per-
formed essentially as described previously (52). NIH 3T3 cells, either serum
starved for 60 h or restimulated for the indicated time with 10% FCS, were
incubated for 10 min with 1% formaldehyde. After addition of 0.1 M glycine, the
cross-linked material was broken with a Dounce homogenizer and sonicated
until the DNA was fragmented to 500- to 800-bp fragments. Immunoprecipita-
tion was performed with ProtG-Sepharose (KPL), using 3 to 5 g of the follow-
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ing antibodies: anti-HMGA2 (36), anti-NF-YB (9), anti-human p120E4F (46),
anti-mouse p120E4F (23), and anti-leader binding protein 1 (anti-LBP1) (9). The
chromatin solution was precleared by treatment with ProtG-Sepharose for 2 h at
4°C, aliquoted, and incubated with the antibodies overnight at 4°C. Before use,
ProtG-Sepharose was blocked twice at 4°C with 1 g of salmon sperm DNA
(sheared at 500 bp) per l and 1 g of BSA per l for 2 h and overnight. PCRs
were performed with the following primers: cyclin A, 5-CTGTAAGATTCCC
GTCGGGCCTTCG-3 and 5-GTAGAGCCCAGGAGCCGCGAG-3; -glo-
bin, 5-GGGCAACTGATAAGGATTCC-3 and 5-AGCACCATGGCCACCA
ATCT-3.
RESULTS
Identification of p120E4F as an HMGA2-interacting protein.
To identify nuclear proteins interacting with HMGA2, a pull-
down assay using a GST-HMGA2 fusion protein with a num-
ber of different transcription factors known to be involved in
growth control and apoptosis was employed. One of the
HMGA2-interacting factors was the E1A-regulated transcrip-
tion factor p120E4F (21). p120E4F is a GLI-Kru¨ppel-related
transcription factor containing six C2H2 zinc finger motifs
which are clustered in two separate regions; two motifs are
contained within an N-terminal domain and mediate the DNA-
binding activity, while the remaining four are grouped within a
central region. As shown in Fig. 1A, in vitro-translated 35S-
labeled p120E4F was retained by GST-HMGA2 but not by GST
alone. Moreover, a bona fide interaction between HMGA2
and p120E4F was observed in the presence of high concentra-
tions of ethidium bromide (Fig. 1A, lanes 5 to 7), which has
been shown to disrupt DNA-dependent protein-protein con-
tact (30).
FIG. 1. p120E4F interacts with HMGA2. (A) 35S-labeled, in vitro-translated p120E4F was incubated with either Sepharose-bound GST (negative
control) (lane 2) or GST-HMGA2 (lane 3). Incubation of 35S-labeled p120E4F with GST-HMGA2 was also performed in the presence of increasing
amounts of ethidium bromide (EtBr) (lanes 5 to 7). The bound proteins were resolved by SDS-PAGE and visualized by autoradiography. Lanes
1 and 4 contain 25% of the in vitro-translated reaction products used in the pull-down experiments. (B) Lysates from 293 cells cotransfected with
5 g of pcDNA3HA-E4F 2.5K and 2 g of pcDNA3-HMGA2 expression vectors, as indicated, were immunoprecipitated (IP) with an anti-
HMGA2 antibody. Total lysates and immunoprecipitates were then analyzed by Western blotting (WB) with an anti-HA (-HA) antibody to reveal
p120E4F (upper panel) or with an anti-HMGA2 antibody to detect HMGA2 protein (lower panel).
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To demonstrate that HMGA2 and p120E4F can also associ-
ate in vivo, vectors expressing HMGA2 and an HA-tagged
p120E4F were cotransfected in 293 cells. Cell lysates were im-
munoprecipitated with anti-HMGA2 antibody, and subse-
quently the immunocomplexes were analyzed by Western blot-
ting with anti-HA antibody. As shown in Fig. 1B, p120E4F
associates with HMGA2 (lane 4). Complex formation was not
detected in the absence of HMGA2 overexpression in the cells
(lane 3). As control, cell lysates used in the experiment were
tested in Western blots for the expression of p120E4F and
HMGA2 proteins (Fig. 1B, lanes 1 and 2). Taken together,
these results clearly demonstrate that HMGA2 and p120E4F
physically associate both in vitro and in vivo.
HMGA2 activates the cyclin A promoter by relieving the
p120E4F-mediated repression. Next we assessed the functional
consequences of the p120E4F-HMGA2 interaction. p120E4F
behaves as a transcriptional repressor, and it recently has been
demonstrated that inhibition of cyclin A is an event required
for p120E4F-dependent cell cycle arrest in G1 and that the
cyclin A promoter activity can be repressed by the binding of
p120E4F to the CRE site (16). Therefore, we asked whether
HMGA2, by associating with p120E4F, could be involved in
controlling the cyclin A promoter. The activity of a reporter
construct containing the promoter region of the human cyclin
A gene cloned upstream of the luciferase gene (CycAwt) (Fig.
2A) was therefore tested in transient-transfection assays. Co-
transfections of CHO cells with the reporter construct and the
p120E4F expression vector result, in agreement with previous
data (16), in a twofold repression of the luciferase activity (Fig.
2B, bar 2). Strikingly, this repression could be completely re-
lieved by cotransfecting increasing amounts of the HMGA2-
expressing vector (bars 3 and 4). Moreover, the transfection of
the HMGA2 expression vector alone, in the absence of
p120E4F expression vector, induced the activity of the reporter
vector (bars 5 and 6). To confirm that the observed promoter
activity was linked to an increase in the amount of the ex-
pressed proteins, aliquots of the lysates were subjected to
Western blot analysis (Fig. 2B, lower panels).
The effect on the cyclin A promoter is specific, since the
activity of a reporter construct containing a cyclin A promoter
mutated within the CRE (CycAmut) (Fig. 2A) was not modified
upon cotransfection of expression vectors for p120E4F,
HMGA2, or a combination of both (Fig. 2C). All of these
results suggest that HMGA2 plays an important role in the
regulation of the cyclin A promoter through the CRE.
HMGA2 activates the expression of the endogenous cyclin A
gene. To further strengthen these observations, we carried out
transfection experiments with SaOS-2 cells, which express very
low levels of HMGA proteins (our unpublished data), and an
HMGA2-expressing vector and analyzed the expression of en-
dogenous cyclin A by a semiquantitative RT-PCR. RNA ex-
tracted from cells transfected with the HMGA2-expressing
vector or with the empty vector was amplified by using primers
for cyclin A and for GAPDH as a control. As can be seen in
Fig. 3A, the expression of cyclin A in HMGA2-transfected cells
(lane 3) was higher than that in control cells (lane 2), while the
expression of GAPDH was constant.
Finally, SaOS-2 cells were transfected with the HMGA2-
expressing vector and immunostained for overexpressed
HMGA2 and endogenous cyclin A. Figure 3B (left panel)
FIG. 2. HMGA2 overexpression relieves the inhibitory effect of
p120E4F on cyclin A transcription. (A) Diagrams of luciferase reporter
genes under the transcriptional regulation of the wild-type human
cyclin A promoter (CycAwt) as well as the promoter mutated at the
CRE (CycAmut). The CRE, CAAT box, and CCRE/CHR elements are
indicated. (B) CHO cells were transiently cotransfected with 1 g of
the luciferase reporter plasmid CycAwt (bars 1 to 6), 1 g of the
expression plasmid pcDNA3HA-E4F 2.5K (bars 2 to 4), and 1 or 2 g
of the expression plasmid pcDNA3HA-HMGA2 (bars 3 and 5 and bars
4 and 6, respectively). One hundred nanograms of pRL-CMV Renilla
luciferase expression vector was included to normalize for transfection
efficiencies. Values are reported as relative luciferase activity. Stan-
dard deviations are indicated for experiments repeated three times.
The amounts of transfected p120E4F and HMGA2 in each sample were
controlled by Western blot (WB) analysis. p120E4F protein was re-
vealed with an anti-p120E4F (-p120E4F) antibody, while the amount of
HMGA2 was controlled by using an anti-HMGA2 antibody. (C) An
identical transfection experiment was carried out with the luciferase
reporter plasmid CycAmut, which contains a cyclin A promoter mu-
tated in the CRE.
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shows a typical result of this experiment. As can be seen in Fig.
3B (right panel), the percentage of cyclin A-expressing cells
which stained negative for HMGA2 was about 40%, while it
increased to about 70% in HMGA2-positive cells. Statistical
analysis with Student’s t distribution revealed that the increase
in the percentage of cyclin A-expressing cells is significant to a
confidence level of greater than 99%. No significant difference
was detected in the percentage of S-phase cells, as detected by
bromodeoxyuridine incorporation, in HMGA2-positive and
-negative cells under these experimental conditions (data not
shown).
Together, these results demonstrate an HMGA2-dependent
induction of the endogenous cyclin A gene.
Binding to HMGA2 requires the two N-terminal zinc-fingers
of p120E4F. As a first step to gain insight into the molecular
mechanism responsible for this effect, we mapped the regions
of p120E4F that are involved in the interaction with HMGA2.
To this end, various deletion mutants of p120E4F cloned in the
pcDNA3HA vector were in vitro translated and tested for their
ability to bind recombinant GST-HMGA2 in pull-down exper-
iments (Fig. 4A). As summarized in Fig. 4B, progressive dele-
tions from the p120E4F C-terminal end (constructs E4F 694,
E4F 551, E4F 427, E4F 60-358, and E4F 262; lanes 1 to 13)
removing residues 262 to 783 had no effect on HMGA2 bind-
ing even though the four-zinc-finger cluster, which is involved
in the binding to p53 (46) and p14ARF (43), was completely
FIG. 3. HMGA2 induces the expression of the endogenous cyclin A. (A) SaOS-2 cells were transfected with 5 g of pcDNA3HA-HMGA2
expression plasmid (lane 3) or with the same amount of pcDNA3HA empty vector (lane 2). At 48 h after transfection, cells were harvested and
the extracted mRNA was amplified by RT-PCR with primers for cyclin A (left panel) and for GAPDH as a control for cDNA quantity and quality
(right panel). In lane 1, the reverse transcriptase was omitted from the RT-PCR. (B) SaOS-2 cells were transfected with 5 g of HMGA2
expression plasmid and immunostained for overexpressed HMGA2 and endogenous cyclin A. Left panel, typical result of this experiment.
HMGA2-expressing cells were identified by using an anti-HA (-HA) antibody directed to the tagged protein (red). Cells expressing endogenous
cyclin A were monitored by using an anti-cyclin A antibody (green). Nuclei were stained with DAPI (blue). Right panel, percentages of cyclin
A-expressing cells among HMGA2-positive or -negative cells. Standard deviations are indicated for experiments repeated three times.
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deleted. A more extended deletion completely abolished the
interaction (construct E4F 162, lanes 14 and 15), suggesting
that the region containing the first two zinc fingers is involved
in the binding with HMGA2. This result was further confirmed
by using the construct E4F 153-299, which contains the two
N-terminal zinc fingers and shows a strong and specific inter-
action with HMGA2 (lanes 20 and 21). Deletions from the
N-terminal end, E4F 60-783 and E4F 350-783, confirm this
result. The weak binding detected with E4F 350-783 is very
likely due to the presence of four zinc fingers that, although
they have a function different from those at the N-terminal
region, share structural similarities.
To map the interaction domains also in vivo, vectors express-
ing wild-type p120E4F and different p120E4F deletions in fusion
with an HA tag were cotransfected with wild-type HMGA2 in
293 cells. As shown in Fig. 5 (upper panel), complex formation
was detected with E4F 262 (lane 3) and E4F 60-358 (lane 5)
but not with E4F 162 (lane 4). As a control, the cell lysates
used in the experiment were tested by Western blotting for the
expression of p120E4F and HMGA2 proteins (Fig. 5, middle
FIG. 4. Binding to HMGA2 requires amino acids 162 to 262 of p120E4F. (A) 35S-radiolabeled, in vitro-translated wild-type (wt) p120E4F and
various E4F N-terminal and C-terminal deletion mutants were incubated with GST-HMGA2 or GST immobilized to Sepharose beads in GST
pull-down assays. The bound proteins were resolved by SDS-PAGE and visualized by autoradiography. Twenty-five percent of the in vitro-
translated reaction products used in the pull-down experiments were included (input). The pull-downs of the E4F deletion mutants with GST gave
negative results and are not shown. (B) Schematic representation of the various E4F constructs used in the pull-down assays and summary of their
abilities to bind HMGA2. The zinc finger domains are shown as black boxes. Numbers refer to amino acids.
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and lower panels, respectively). These results are consistent
with those obtained in vitro and clearly demonstrate that bind-
ing in vivo requires the region containing the two N-terminal
zinc fingers of p120E4F.
Binding to p120E4F requires amino acids 44 to 63 of
HMGA2. To identify the domains in HMGA2 that interact
with p120E4F, we generated deletions of the HMGA2 protein
and tested for their ability to interact with in vitro-translated
p120E4F in a far-Western assay. Data obtained from the ex-
periment shown in Fig. 6A (upper panel) demonstrate that the
interaction with p120E4F is maintained when the acidic C-
terminal tail is removed (HMGA294, HMGA283, and
HMGA2MAD). Similarly, the deletion of the region containing
the third AT hook (HMGA273) is not effective, while further
deletions (HMGA254 and HMGA243) completely abolish the
binding. As a control, a Western blot analysis was performed in
parallel with an antibody raised against a peptide, derived from
the N-terminal sequence of HMGA2, common to all the re-
combinant proteins (Fig. 6A, lower panel).
These data, summarized in Fig. 6B, indicate that the region
between the second and third AT hooks, from amino acid 54 to
73 of HMGA2, is critical for the interaction with p120E4F. Two
peptide sequences spanning the region presumably involved in
the interaction were expressed within the active site of the E.
coli thioredoxin (TrxA) to assess which region was sufficient for
binding with p120E4F. TrxA was chosen since its scaffold pro-
vides conformational constraint and stability to short peptide
sequences (12). Figure 6C shows a GST pull-down experiment
in which peptides from amino acid 44 to 63 and from amino
acid 53 to 72 of the HMGA2 sequence were expressed within
the TrxA protein fused to GST and incubated with in vitro-
translated p120E4F. GST-TRX44/63 (lane 4) was able to bind
p120E4F, whereas GST-TRX53/72 (lane 5) behaved as the neg-
ative control GST-TRXA (lane 3), demonstrating that the
region from amino acid 44 to 63 within HMGA2 is necessary
and sufficient for p120E4F binding. These data indicate that, in
the context of HMGA2, the minimal region required for spe-
cific interaction with p120E4F corresponds to the second AT
hook flanked by the spacer region between the second and
third AT hooks, revealing, in this respect, a behavior similar to
that shown for HMGA2 and NF-B (36).
HMGA2 interferes with E4F binding to the CRE element.
We then investigated at the molecular level how the effect of
HMGA2 on the cyclin A promoter could be explained. To this
end, we tested by EMSA the effect of a purified HMGA2wt
recombinant protein on E4F binding to the cyclin A CRE site
(Fig. 7). An affinity-purified GST-E4F 60-358 fusion protein
gave rise to a protein-DNA complex in a dose-dependent fash-
ion (lanes 2 to 5). This complex is specific, since it was com-
peted by an excess of the self cold probe CycAwt (lane 6) but
not by the mutant CycAmut probe (lane 7). The E4F-DNA
complex was then tested with increasing amounts of HMGA2wt
recombinant protein (lanes 8 to 11). As can be seen, increasing
amounts of HMGA2wt progressively inhibited the formation of
the E4F-DNA complex, which disappeared with the highest
concentration of HMGA2wt added (lane 11) while in parallel a
fast-migrating complex appeared. This complex is due to the
association of HMGA2wt with the DNA, since it also appears
in the absence of GST-E4F 60-358 fusion protein (lanes 17 to
19), and is specific, since mutations that replace the AT bases
present within and 5 to the CRE in GC abolish the binding of
HMGA2wt to the DNA (data not shown). It is interesting that
there is a supershifted complex (lane 10), derived from the
association of HMGA2wt with the E4F-DNA complex, as an
intermediate before the complete disappearance of the E4F-
DNA complex. The HMGA2wt-mediated effect is specific,
since the addition of BSA had no effect on E4F-DNA complex
formation (lanes 12 to 15).
HMGA2 binds in vivo to the cyclin A promoter. To further
demonstrate that HMGA2 could bind to the cyclin A pro-
moter, we performed chromatin immunoprecipitation experi-
ments with anti-HMGA2 affinity purified antibodies (Fig. 8A).
We used mouse NIH 3T3 fibroblasts, which can be arrested in
G0 by incubation with 0.5% FCS and restimulated upon serum
addition to reenter in the cell cycle. We took samples at dif-
ferent time points (6, 12, 18, and 24 h) poststimulation, corre-
sponding to the G1, G1/S, S, and G2/M phases of the cell cycle,
FIG. 5. Mapping of the interaction domains of p120E4F in vivo.
Lysates from 293 cells cotransfected with 5 g of pcDNA3HA vectors,
expressing wild-type (wt) p120E4F and different p120E4F deletion mu-
tants, and with 2 g of pcDNA3-HMGA2 expression vector (lanes 2 to
5) or empty vector (lane 1) were immunoprecipitated (IP) with an
anti-HMGA2 (-HMGA2) antibody. The immunoprecipitates were
then analyzed by Western blotting (WB) with an anti-HA antibody
(upper panel, lanes 1 to 5). Total lysates used in the immunoprecipi-
tation experiment were controlled for the amount of transfected E4F
constructs with an anti-HA antibody (middle panel). Transfected
HMGA2 protein was revealed with an anti-HMGA2 antibody (lower
panel).
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as previously shown and checked by fluorescence-activated cell
sorter analysis (reference 9 and data not shown). The immu-
noprecipitated DNA was used to amplify the cyclin A pro-
moter, as well as an -globin promoter that is not expressed in
these cells. As shown in Fig. 8A, compared to the control
antibody, binding of HMGA2 to cyclin A is negligible in G0
and G1 cells but becomes apparent at 18 h, corresponding to
S-phase cells, while at 24 h the binding is no longer visible. We
could not observe any association of HMGA2 with the control
-globin promoter at the different time points.
If HMGA2 competes with p120E4F for the binding to the
cyclin A promoter, as suggested by the EMSA experiments,
then the association of these two proteins with the promoter
could be mutually exclusive. To test this hypothesis, antibodies
against human and mouse p120E4F were used to immunopre-
cipitate chromatin from growth-arrested and serum-stimulated
NIH 3T3 fibroblasts, and the immunoprecipitated DNA was
used to amplify the cyclin A promoter. As shown in Fig. 8B,
both human and mouse antibodies failed to detect p120E4F
associated with the promoter before 24 h, when essentially all
cells have passed S phase and are in G2/M or have reentered
G1 (reference 9 and data not shown). In particular, p120
E4F is
not bound at 18 h, when the promoter is active and HMGA2 is
bound. As a control for cell cycle progression, we used anti-
NF-YB antibodies; the protein was found associated in G1/S, S,
and G2/M as previously described (9). These data document
the specific, phase-dependent, and mutually exclusive associa-
tion of HMGA2 and p120E4F with the cyclin A promoter and
FIG. 6. Binding to p120E4F requires amino acids 44 to 63 of HMGA2. (A) Upper panel, purified recombinant wild-type (wt) HMGA2 and
several HMGA2 deletion mutants were probed in a far-Western blot analysis with 35S-radiolabeled in vitro-translated p120E4F. Lower panel,
Western blot analysis of the membrane with an anti-HMGA2 antibody. (B) Schematic representation of the various HMGA2 constructs used in
the far-Western experiment and summary of their abilities to bind p120E4F. The functional domains of HMGA2 and the ectopic sequence fused
to HMGA2 described for a uterine leiomyoma (29) are indicated. Numbers refer to amino acids. (C) 35S-radiolabeled, in vitro-translated p120E4F
was incubated with GST-HMGA2 (positive control) (lane 2), GST-TRXA (negative control) (lane 3), GST-TRX44/63 (lane 4), and GST-
TRX53/72 (lane 5) in a GST pull-down assay. All of the GST proteins used were bound to Sepharose beads. The bound proteins were resolved
by SDS-PAGE and visualized by autoradiography. Lane 1 contains 25% of the in vitro-translated reaction products used in the pull-down assay.
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show the binding of HMGA2 under conditions in which the
promoter is transcriptionally active (26).
DISCUSSION
Growth is one of the fundamental aspects of the develop-
ment of an organism. This process is tightly controlled by the
coordination of proliferation, differentiation, and apoptosis,
with disruption of these processes commonly resulting in tu-
mor formation.
In this study we report that HMGA2, an architectural tran-
scription factor which is directly involved in cell proliferation
and neoplastic transformation, associates with the transcrip-
tional repressor p120E4F, resulting in the induction of the cy-
clin A gene. Cyclin A is a key factor controlling cell cycle
progression both at the S phase entry and at the G2/M transi-
tion by binding to cdk2 and cdc2 kinases, respectively (37, 45).
HMGA2-mediated cyclin A induction is due to interference
with p120E4F repressing activity. Although several reports in-
dicate that HMGA proteins are architectural factors, able to
enhance the DNA binding of DNA-interacting proteins pro-
moting the formation of enhanceosomes, data have been pub-
lished showing an inhibitory effect of HMGA on DNA binding
of other factors, usually by sterically blocking the functional
binding of transcription factors to their recognition sites in
gene promoters (42). Would it thus be possible to extend the
mechanism that we found for the cyclin A gene to other
p120E4F target genes? Although the cyclin A gene is the only
cellular target thus far demonstrated for p120E4F, it is likely
that other genes involved in the control of cell cycle progres-
sion are regulated by p120E4F, as ectopic expression of p120E4F
can induce cell cycle arrest at the G1/S and G2/M transitions
even when cyclin A mRNA and protein levels are not reduced
(22, 44). The association of HMGA2 with p120E4F through the
region containing the DNA-binding domain could therefore
constitute a switch that displaces p120E4F-containing com-
plexes from cyclin A and other, yet-to-be-defined, p120E4F
target genes. According to this hypothesis, the expression of
FIG. 7. HMGA2 interferes with E4F binding to the CRE element. Increasing amounts of purified GST-E4F 60-358 fusion protein (0.3, 0.6,
1.2, and 2 pmol [lanes 2 to 5, respectively]) were incubated with the 32P-radiolabeled CycAwt oligonucleotide (from bp 140 to 112 relative to
the most 3 transcription initiation site) in an EMSA experiment. Lane 1, free probe. Competitions were performed on the maximal amount of
GST-E4F 60-358 tested by using a 100-fold molar excess of unlabeled wild-type CycAwt (lane 6) or CRE-mutated competitor CycAmut (lane 7).
Increasing amounts of purified recombinant wild-type (wt) HMGA2 (0, 4, 8, and 12 pmol [lanes 8 to 11, respectively]) or BSA (0, 4, 8, and 12 pmol
[lanes 12 to 15, respectively]) were incubated with a fixed amount of GST-E4F 60-358 (2 pmol). Increasing amounts of purified recombinant
wild-type HMGA2 (0, 4, 8, and 12 pmol [lanes 16 to 19, respectively]) were also incubated with the CycAwt probe in the absence of GST-E4F
60-358. Lane 16, free probe.
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HMGA2 in human tumors could inactivate the repressing ef-
fect of p120E4F on cell growth.
Another important consideration refers to the region of
HMGA2 involved in p120E4F protein-protein interaction. This
is a very short region comprising and flanking the second AT
hook, which we have previously shown to be involved in the
interaction with NF-B (36). Moreover, the corresponding re-
gion in HMGA1 is involved in the interaction with other tran-
scription factors as well. Two lysine residues within this region
were shown to be acetylated by CBP/p300 and P/CAF and to
be critical for the disassembly and assembly of the enhanceo-
some at the beta interferon gene (34). This short domain,
which can be targeted by posttranslational modifications, plays
an important role in HMGA proteins in establishing connec-
tions with nuclear factors and is therefore crucial for the ar-
chitectural role played by these factors.
HMGA2-mediated cyclin A gene induction occurs through
the CRE element. The cyclin A promoter is regulated during
G0 and G1 by contiguous cis-acting elements, the CDE-CHR
bipartite element (8, 27, 38). Different transcription factors,
among which are the pocket proteins (pRb and p107), have
been shown to be involved in the binding to these elements, but
the mechanism remains to be characterized and is still a matter
of controversial discussion (27, 38). The cyclin A promoter
region also contains a CRE site. Several reports show that the
CRE site plays an important role in transcriptional activation
of the cyclin A gene (5, 13, 35, 48, 49). Most studies indicate
that CRE is constitutively occupied in G1-phase cells, and it
has been proposed that the CDE-CHR could act in concert
with CRE to confer proper cell cycle regulation to cyclin A
gene expression (49). The CRE is recognized by CREB and
ATF family members that belong to the family of basic leucine
zipper proteins, which are able to form homo- and het-
erodimers and cross-family heterodimers with members of the
AP1 family. As a consequence, different factors binding to
CRE have been identified in different cell types. It has been
shown that the different compositions of the subunits, as well
as their posttranslational modifications, are involved in the
response to different stimuli (e.g., serum induction or cyclic
AMP) acting through the CRE to regulate the cyclin A gene
(5, 13, 35, 48, 49). The CRE site is also recognized by p120E4F,
raising the question of how the access of p120E4F to this site
and subsequent transcriptional regulation are controlled (16).
Interestingly, it has been hypothesized that auxiliary proteins,
such as HMGA, could be possible regulators (16). Indeed,
HMGA proteins can modulate the access of transcription fac-
tors to DNA and are regarded as highly connected nodes of
protein-DNA and protein-protein interactions that influence a
diverse array of normal and pathological processes, participat-
ing in a wide variety of nuclear processes, ranging from chro-
mosome and chromatinic mechanics to architectural transcrip-
tion factors (40). In this report we show that HMGA2 activates
the cyclin A gene through the CRE and that this effect also
occurs in the absence of ectopic expression of p120E4F. This
could be explained by assuming a competition with the endog-
enous p120E4F, but it could also be due to an effect of HMGA2
on other transcription factors binding to CRE. Indeed, it has
been demonstrated that HMGA1a could enhance the binding
of basic leucine zipper-containing factors, increasing the sta-
bility of dimers (14). In addition, we demonstrated by EMSA
experiments that HMGA2 can enhance the binding of ATF-2
to the CRE (data not shown). Therefore, we propose that
HMGA2 regulation of the cyclin A gene occurs by modulating
the access of transcription factors binding to the CRE. This
occurs through protein-protein interactions, but since we dem-
onstrated that HMGA2 interacts with DNA in a region con-
taining the CRE, it is also possible that structural modifications
of DNA induced by HMGA could play a role in this effect. In
FIG. 8. Association of HMGA2 and p120E4F with the cyclin A
promoter is regulated during the cell cycle. (A) Chromatin immuno-
precipitation analysis of HMGA2 binding to the cyclin A promoter in
vivo was performed with NIH 3T3 cells. Immunoprecipitations of
sonicated, cross-linked chromatin samples, taken at G0 and at different
time points (6, 12, 18, and 24 h) poststimulation, corresponding to the
G1, G1/S, S, and G2/M phases of the cell cycle, were performed with
antibodies raised against HMGA2 and LBP1, a cellular DNA-binding
protein used as a negative control. DNAs corresponding to cyclin A
(left panel) and to -globin used as negative control (right panel) were
PCR amplified with the indicated oligonucleotides (see Materials and
Methods). The input chromatin taken prior to immunoprecipitation
was used as a template for PCR amplification (input). (B) Chromatin
immunoprecipitation analysis of p120E4F binding to the cyclin A pro-
moter was performed as described for panel A with antibodies against
NF-YB, human p120E4F, mouse p120E4F, and LBP1 as a negative
control.
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this scenario, HMGA2 could therefore function by shifting the
balance between p120E4F-mediated repression and CREB/
ATF activators binding to the CRE, favoring the latter (Fig. 9).
Importantly, in this view HMGA2 is not constitutively bound
to the cyclin A promoter throughout the cell cycle. Chromatin
immunoprecipitation experiments in fact show HMGA2 bound
to the promoter only at 18 h after serum induction, which
corresponds to the time when the cyclin A gene is activated. In
fibroblasts stimulated by serum, HMGA2 is a delayed-early-
responsive gene with peak expression at 7.5 to 20 h (31). The
expression of HMGA2 is therefore modulated during the pro-
gression through the cell cycle, and its kinetic is compatible
with the activation of the cyclin A gene. Moreover, the timely
regulated association of p120E4F with the promoter is consis-
tent with the proposed model, since p120E4F binds in G2/M but
not during S phase, when the promoter is occupied by HMGA2
and the gene is active. Interestingly, p120E4F is not detected in
G0, suggesting that is not implicated in cyclin A repression in
growth-arrested cells.
Repression of the cyclin A promoter in quiescent cells was
found to be associated with recruitment of the E2F-4 transcrip-
tional repressor (reference 39 and references therein). Our
finding that another repressor, p120E4F, associates with the
cyclin A promoter defines a second level of repressive regula-
tion for this gene.
Cyclin A is the first identified HMGA2 target gene involved
in neoplastic transformation. Our finding that cyclin A is a
direct target gene of HMGA2 is consistent with the role pro-
posed for HMGA2 in cell transformation and cell growth dur-
ing embryogenesis. The HMGA2 protein has been implicated
in the pathogenesis of a variety of benign solid human tumors
(2, 20, 47, 50), and its role has been demonstrated by using
transgenic mice overexpressing wild-type HMGA2 or HMGA2
mutants (1, 3, 6, 18, 19). Moreover, it was reported that the
pygmy phenotype in mice was caused by the disruption of both
Hmga2 alleles (55). These mice show a small size and a drastic
reduction of body fat content, and, interestingly, Hmga2/
embryonic fibroblasts have a decreased rate of cell prolifera-
tion. This suggested an involvement of HMGA2 in the control
of critical steps of the progression through the cell cycle, and
our results involve cyclin A as a possible effector of HMGA2 in
this phenotype.
In conclusion, this work establishes cyclin A as a mediator of
HMGA2-dependent cell cycle regulation. The characterization
of other molecular partners of HMGA2 will allow definition of
the role played by this factor in cell proliferation and tumori-
genesis.
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